Rhythm Biosciences Limited (ASX:RHY)

Market Cap	57.24M +134.7%
Revenue (ttm)	3.19M +88.9%
Net Income	-3.83M
EPS	-0.01
Shares Out	327.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	371,205
Average Volume	880,725
Open	0.1900
Previous Close	0.1900
Day's Range	0.1750 - 0.1900
52-Week Range	0.0470 - 0.2100
Beta	0.26
RSI	60.65
Earnings Date	Feb 18, 2026

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RHY

Financial Performance

In fiscal year 2025, Rhythm Biosciences's revenue was 3.19 million, an increase of 88.85% compared to the previous year's 1.69 million. Losses were -3.83 million, -44.15% less than in 2024.